Befejeződött4. fázis
Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy
Key facts
- Where
- Balatonfured, Budapest, Budapest XII, Budapest XIII, Pécs és Szeged, MagyarországSee the 6 sites
- Phase
- 4. fázis
Where in Magyarország
- Balatonfueredi Allami SzivkorhazBalatonfured, MagyarországNo longer taking part
- Gottsegen National Cardiovascular CenterBudapest, MagyarországNo longer taking part
- Semmelweis UniversityBudapest XII, MagyarországNo longer taking part
- Central Hospital Of Northern Pest Military HospitalBudapest XIII, MagyarországNo longer taking part
- University of PecsPécs, MagyarországNo longer taking part
- University of SzegedSzeged, MagyarországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Myokardia Inc.
- Trial code
- EU 2022-502316-36-00
- Record updated
- 2024. február 12.
- Original description
The purpose of this study is to see if mavacamten treatment reduces the heart wall (ventricle) thickness and size of the upper heart chamber (atria) on imaging studies by cardiac magnetic resonance (CMR).Read full original descriptionShow less
MEMENTO-A Phase 3b/4 Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to assess the impact on Myocardial Structure with Cardiac Magnetic Resonance Imaging (CMR)
The purpose of this study is to see if mavacamten treatment reduces the heart wall (ventricle) thickness and size of the upper heart chamber (atria) on imaging studies by cardiac magnetic resonance (CMR).
Inclusion: This trial will assess elegible adults with symptomatic oHCM (NYHA Funtional Class II or III).
Exclusion: Adults with no symptomatic oHCM (NYHA Funtional Class II or III).